op of the morning to you, and a fine one it is as we approach the middle of the week. After all, getting to this point is an accomplishment, which means that a celebratory cup of stimulation is in order to help us move along. And why not? Just consider the alternatives. Meanwhile, another busy day lies ahead. On that note, here are some items of interest. Hope you have a smashing day and keep us in mind if you hear something juicy …

Novartis may face fines or a sales ban of up to six months on drugs sold in South Korea due to a bribery case, the Investor reports. South Korea’s Health Ministry plans to announce punitive measures against the Korean unit over allegations company executives illegally paid doctors kickbacks in return for prescribing its drugs. The Ministry of Food and Drug Safety last week imposed a $177,000 fine and suspended sales of 12 drugs for three months.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy